HGS advanced HGS-ETR1 (mapatumumab) to a proof-of-concept phase,
consisting of three randomized chemotherapy combination trials to evaluate
its potential in the treatment of specific cancers:
-- Advanced multiple myeloma. The enrollment and initial dosing of 105
patients has been completed in a randomized Phase 2 trial of HGS-ETR1
in combination with Velcade (bortezomib).
-- Advanced non-small cell lung cancer. In December 2007, HGS initiated
dosing of approximately 105 patients in a randomized Phase 2 trial of
HGS-ETR1 in combination with paclitaxel and carboplatin as first-line
-- Hepatocellular cancer. In April 2008, HGS announced plans to initiate
a randomized trial of HGS-ETR1 in combination with Nexavar (sorafenib)
in patients with advanced hepatocellular cancer.
HGS-ETR1 is the most advanced of any product in development that targets the TRAIL apoptosis pathway.
HGS added the new opportunity to develop and commercialize HGS1029 and other small-molecule IAP inhibitors for the treatment of cancer through a strategic transaction entered into in December 2007 with Aegera Therapeutics. The HGS TRAIL receptor antibodies and small-molecule IAP inhibitors represent two different highly targeted approaches targeting different points in the apoptosis pathway. Each is able to cause cancer cells to die selectively. When IAP (inhibitor of apoptosis) proteins are over-expressed in cancer cells, they can help cancer cells resist apoptosis and resume growth and proliferation. The IAP inhibitors are a novel class of compounds that block the activity of IAP proteins, thus allowing apoptosis to proceed and causing the cancer cells to die.
The initiation of dosing is
|SOURCE Human Genome Sciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved